JP6161494B2 - 血漿タンパクを含有する筋萎縮改善用経口組成物及び筋萎縮改善剤 - Google Patents
血漿タンパクを含有する筋萎縮改善用経口組成物及び筋萎縮改善剤 Download PDFInfo
- Publication number
- JP6161494B2 JP6161494B2 JP2013204591A JP2013204591A JP6161494B2 JP 6161494 B2 JP6161494 B2 JP 6161494B2 JP 2013204591 A JP2013204591 A JP 2013204591A JP 2013204591 A JP2013204591 A JP 2013204591A JP 6161494 B2 JP6161494 B2 JP 6161494B2
- Authority
- JP
- Japan
- Prior art keywords
- muscle atrophy
- plasma protein
- improving
- oral composition
- atrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004506 Blood Proteins Human genes 0.000 title claims description 84
- 108010017384 Blood Proteins Proteins 0.000 title claims description 84
- 201000000585 muscular atrophy Diseases 0.000 title claims description 84
- 206010028289 Muscle atrophy Diseases 0.000 title claims description 71
- 230000020763 muscle atrophy Effects 0.000 title claims description 71
- 239000000203 mixture Substances 0.000 title claims description 46
- 239000003795 chemical substances by application Substances 0.000 claims description 48
- 230000037396 body weight Effects 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 37
- 239000003826 tablet Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 10
- 235000015110 jellies Nutrition 0.000 claims description 10
- 239000008274 jelly Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 210000003205 muscle Anatomy 0.000 description 44
- 239000000047 product Substances 0.000 description 34
- 241000700159 Rattus Species 0.000 description 24
- 235000013305 food Nutrition 0.000 description 22
- 206010066871 Disuse syndrome Diseases 0.000 description 21
- 238000000034 method Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 14
- 210000002414 leg Anatomy 0.000 description 13
- 241000282412 Homo Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 206010003694 Atrophy Diseases 0.000 description 10
- 230000037444 atrophy Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 235000013402 health food Nutrition 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000001076 sarcopenia Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241000282898 Sus scrofa Species 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 238000009395 breeding Methods 0.000 description 7
- 230000001488 breeding effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 241000282887 Suidae Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- -1 pH adjusters Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010016717 Fistula Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000716 Acceptable daily intake Toxicity 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010056720 Muscle mass Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013384 milk substitute Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明の筋萎縮改善用経口組成物は、1日投与単位中に、血漿タンパクを0.3mg/kg体重以上の割合で含有することを特徴とする。本発明の筋萎縮改善用経口組成物を摂取することにより、廃用症候群により萎縮した筋肉を早く回復させることができる。
前記血漿タンパク又はその粉末物の投与量及び摂取量は、後記のラットを用いた実験例結果と一日摂取許容量(Acceptable Daily Intake、ADI)とから、定めた数値範囲である。
そして、この一日摂取許容量の概念を基に、その有効成分のヒトに対する投与量・摂取量について、効果を表す有効成分の最小の投与量(最小有効量)を決定することが可能である。
本発明の筋萎縮改善剤は、血漿タンパクを含有することを特徴とし、廃用症候群により萎縮した筋肉を早く回復させることが可能である。
特定保健用食品:特保(とくほ)。体の生理学的機能等に影響を与える保健機能成分を含み、特定の効能が認められ、その効能を表示することを消費者庁から許可された食品。商品には、特定の効能が期待できる旨の文言と、「消費者庁許可特定保健用食品」等の証票が表示される。
ラットを用いて下肢廃用性モデルの筋委縮に対する被験物質の改善効果を検討した。
血漿タンパクとして、下記スプレードライ・ブタ血漿(粉末物)を使用した。
保管方法:室温保管
媒体の名称:水道水
(2)投与液の調製方法
調製濃度
必要量秤量し水道水に混和して100mg/mLの濃度に調製した。
K-1は、タンパクとして、ブタ血漿を含まず、カゼインのみを含む投与素材である。
一週間分の必要量をまとめて調製した。調整後の溶液は冷蔵保管し、1日の必要量を小分けし、室温に戻して投与した。
動物
種:Wistar系ラット
性別:雄
使用動物数:30匹
週齢(入手時):8週齢
供給源:日本エスエルシー株式会社
マウス及びラットを用いた廃用性モデルの検討は、多々報告があり、バックグラウンドデータの豊富なラットを選択した。尾部に油性マジックインクで動物番号を示す棒線を入れ個体識別するとともに,試験番号,性別,動物番号を記入したラベルを各ケージに貼付して、個体を識別した。
飼育室の環境条件
飼育室名:マウス、ラット飼育室
温度:24±2℃
湿度:50%±20%
換気回数:13回/時間
照明時間:12時間/日(7〜19時)
ケージ
種類:プラスチック製、蓋ステンレス製ケージ(136mm W×208mm D×115mm H)
収容匹数/ケージ:1匹/ケージの個別飼育
床敷き交換頻度:各飼育ケージの床敷き交換は、週2回行った。
種類:市販固型飼料CE-2(日本クレア(株))
給餌方法:1日約50g/匹を通常給餌した。
種類:水道水
給水方法:給水瓶にて自由に摂取させた。
ラットの群構成と被験物質の投与量
各ラット群に対して、100mg/mL濃度の被験物質を、下記量で投与した。
処置及び下肢筋肉量の測定
馴化飼育後、動物をペントバルビタール(20mg/kg)の腹腔内投与により麻酔を施した。
上記結果より、通常の体重60kgのヒトに対する血漿タンパク又はその粉末物の最小有効量は、上記値の1/100量である、0.3mg/kg体重/日程度以上の範囲となる。つまり、本発明の筋萎縮改善用経口組成物に含まれる血漿タンパク又はその粉末物の割合としては、通常の体重60kgのヒトに対して、1日投与単位(1日摂取単位)中に、血漿タンパク又はその粉末物が0.3mg/kg体重程度以上の範囲で含まれると、ヒトに対して廃用症候群により萎縮した筋肉を早く回復させることができると考えられる。
以下の処方により、血漿タンパクを含有する筋萎縮改善用経口組成物及び筋萎縮改善剤(健康食品等)を調製した。
Claims (5)
- 1日投与単位中に、血漿タンパクを0.3mg/kg体重以上の割合で含有する筋萎縮改善用経口組成物。
- 粉末状、顆粒状、錠剤状、丸剤状、カプセル状、ゼリー状及び液状から選ばれる形態を有する、請求項1に記載の筋萎縮改善用経口組成物。
- 血漿タンパクを含有する筋萎縮改善剤。
- 1日投与単位中に、血漿タンパクを0.3mg/kg体重以上の割合で含有する、請求項3に記載の筋萎縮改善剤。
- 錠剤、丸剤、散剤、粉末剤、顆粒剤、カプセル剤及びゼリー剤から選ばれる投与形態を有する、請求項3又は4に記載の筋萎縮改善剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013204591A JP6161494B2 (ja) | 2013-09-30 | 2013-09-30 | 血漿タンパクを含有する筋萎縮改善用経口組成物及び筋萎縮改善剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013204591A JP6161494B2 (ja) | 2013-09-30 | 2013-09-30 | 血漿タンパクを含有する筋萎縮改善用経口組成物及び筋萎縮改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015067583A JP2015067583A (ja) | 2015-04-13 |
JP6161494B2 true JP6161494B2 (ja) | 2017-07-12 |
Family
ID=52834631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013204591A Expired - Fee Related JP6161494B2 (ja) | 2013-09-30 | 2013-09-30 | 血漿タンパクを含有する筋萎縮改善用経口組成物及び筋萎縮改善剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6161494B2 (ja) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569447B2 (en) * | 2000-03-24 | 2003-05-27 | Trouw Nutrition Usa, Llc | Combination of plasma and hyperimmunized products for increased performance |
JP2011184314A (ja) * | 2010-03-04 | 2011-09-22 | Snow Brand Milk Products Co Ltd | 筋肉萎縮防止剤 |
-
2013
- 2013-09-30 JP JP2013204591A patent/JP6161494B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2015067583A (ja) | 2015-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6822734B2 (ja) | 経口補水組成物とその方法 | |
JPH082268B2 (ja) | メチルスルホニルメタンを含む食餌製品およびその使用 | |
Rafiee-Tari et al. | Effect of milk protein composition and amount of β-casein on growth performance, gut hormones, and inflammatory cytokines in an in vivo piglet model | |
US5516798A (en) | Method for treating diarrhea and a composition therefor | |
JP6265335B2 (ja) | 骨密度増加剤、破骨細胞活性抑制剤及び骨リモデリング改善剤 | |
JP2006515879A (ja) | 哺乳類による栄養利用を向上するための方法およびその中で使用するための組成物 | |
JP6161494B2 (ja) | 血漿タンパクを含有する筋萎縮改善用経口組成物及び筋萎縮改善剤 | |
DK1776956T3 (en) | An agent for the prevention and / or treatment of calcium deficiency | |
WO2017186954A1 (en) | Method for the improvement of speed and endurance capacity | |
DK2858653T3 (en) | Cow's milk as minimal enteral nutrition for premature infants. | |
Tonozzi | Nutritional status | |
JP6071988B2 (ja) | 身体活動促進剤 | |
JP2018184477A (ja) | 筋肉増強剤 | |
JP2000239179A (ja) | 運動時のアンモニア生成抑制による運動能力の向上 | |
US10188678B2 (en) | Composition comprising cinnamaldehyde and zinc to improve swallowing | |
BE1020455A3 (nl) | In glycoproteine verrijkte samenstelling als voedings- en/of diervoederadditief en/of als therapeutisch middel. | |
JP2011063552A (ja) | 身体活動促進剤 | |
JP2015189683A (ja) | アキノワスレグサを含有する筋肉量増加剤及び筋萎縮改善剤 | |
Stratton-Phelps | Nutritional management of the hospitalised horse | |
JPWO2017159741A1 (ja) | 行動体力向上剤 | |
JP2018519322A (ja) | 海洋ペプチドおよび筋肉の健康 | |
Perlman | ADDITIONS TO ORAL FLUIDS | |
WO2014157153A1 (ja) | 筋萎縮防止剤 | |
Hughes | Catch-up growth in the limbs of rats undernourished for different lengths of time during suckling | |
JP2007055979A (ja) | ロタウイルス感染による下痢からの回復促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160829 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170523 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6161494 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |